Renal Cell Carcinoma | Treatment Sequencing | US | 2019
KEY BENEFITS AND USES
- Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.
- Drill down into physicians’ treatment sequences and understand who to position against or how to defend share.
- Identify untapped treatment scenarios and key competitors to aid trial design.
- Evaluate unique disease-specific treatment patterns and dynamics to plan and manage sales and marketing resources and execute commercialization messages.
- Discover untapped populations to expand product share and drive strategic decisions.
QUESTIONS ANSWERED
• Where is my product positioned vs. competitors in the treatment journey?
• What are physicians’ most frequent treatment sequences—who is
benefiting and how can I defend my assets share and position?
• What are the market-relevant treatment scenarios according to oncology
experts?
• Where are the untapped business opportunities that I can capitalize
upon?
• How can I optimize trial design and ensure a competitive edge for my
pipeline asset?
GEOGRAPHIES
United States
PRIMARY MARKET RESEARCH
Survey of ~100 U.S. physicians
2019 COVERAGE
Colorectal Cancer (US)
Multiple Myeloma (US)
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia (US)
Non-Small-Cell Lung Cancer (US)
Ovarian Cancer (US)
Prostate Cancer (US)
Renal Cell Carcinoma (US)
KEY FEATURES
- Market-relevant treatment scenarios and subpopulations from oncology experts
- Drug share and treatment rates mapped to treatment journey using physician survey data
- Physicians’ most frequently selected treatment sequences
- Access to expert oncology analysts for bespoke support
PRODUCT DESCRIPTION
Treatment Sequencing provides disease-specific, sequential treatment
patterns in market-relevant treatment scenarios and drug share mapped to
treatment journey. The quantitative sequencing analysis illuminates drug
positioning through primary market research-based insights from physicians
and DRG oncology experts’ assumptions.
